Teleflex Incorporated (NYSE:TFX) Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $263.38, for a total value of $658,450.00. Following the completion of the sale, the director now owns 10,583 shares in the company, valued at approximately $2,787,350.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Teleflex Incorporated (NYSE:TFX) traded up $9.38 during midday trading on Wednesday, hitting $272.31. The stock had a trading volume of 344,509 shares, compared to its average volume of 243,209. The company has a market capitalization of $12,250.00, a price-to-earnings ratio of 49.15, a P/E/G ratio of 1.94 and a beta of 1.09. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. Teleflex Incorporated has a one year low of $162.79 and a one year high of $272.46.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.11. The company had revenue of $534.70 million for the quarter, compared to analyst estimates of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.80 earnings per share. research analysts predict that Teleflex Incorporated will post 8.36 earnings per share for the current fiscal year.

TFX has been the topic of several research analyst reports. Stephens restated a “buy” rating and issued a $270.00 price objective (up previously from $230.00) on shares of Teleflex in a research note on Monday, September 25th. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Piper Jaffray Companies initiated coverage on Teleflex in a research note on Friday, November 10th. They issued an “overweight” rating and a $295.00 price objective on the stock. Finally, Jefferies Group upped their price objective on Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $274.44.

Several hedge funds and other institutional investors have recently made changes to their positions in TFX. Toronto Dominion Bank increased its stake in shares of Teleflex by 14.5% during the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 70 shares during the period. Advisory Services Network LLC increased its stake in shares of Teleflex by 933.8% during the second quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after purchasing an additional 747 shares during the period. Cornerstone Capital Management Holdings LLC. bought a new position in shares of Teleflex during the second quarter worth approximately $175,000. Archford Capital Strategies LLC increased its stake in shares of Teleflex by 29,025.0% during the second quarter. Archford Capital Strategies LLC now owns 1,165 shares of the medical technology company’s stock worth $217,000 after purchasing an additional 1,161 shares during the period. Finally, Coldstream Capital Management Inc. acquired a new stake in Teleflex during the third quarter worth approximately $226,000. Institutional investors own 89.29% of the company’s stock.

TRADEMARK VIOLATION WARNING: “George Babich, Jr. Sells 2,500 Shares of Teleflex Incorporated (TFX) Stock” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with's FREE daily email newsletter.